Want to see MGNX full AI Analyst Report?
MGNX Stock Chart & Stats
$4.04
$0.21(5.68%)
At close: 4:00 PM EDT
$4.04
$0.21(5.68%)
Day’s Range― - ―
52-Week Range$1.29 - $5.08
Previous CloseN/A
Volume200.74K
Average Volume (3M)586.35K
Market Cap
$228.68M
Enterprise Value$318.75M
Total Cash (Recent Filing)$173.31M
Total Debt (Recent Filing)$35.09M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Nov 04, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding63,700,188
10 Day Avg. Volume563,664
30 Day Avg. Volume586,348
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.83
Price to Sales (P/S)0.68
P/FCF Ratio-1.23
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue1.90
Enterprise Value/Gross Profit3.77
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$7.00Price Target Upside73.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$117.49M
Bulls Say, Bears Say
Bulls Say
Improving Revenue And LossesTTM revenue growth and a substantial narrowing of net losses indicate meaningful improvement in operating performance. The progress may provide a stronger base for future operating leverage and reduce the distance to breakeven, although profitability remains unachieved.
Improved LeverageLower debt-to-equity and manageable total debt improve financial flexibility relative to the prior year. A less leveraged balance sheet can reduce financing pressure and preserve capacity to support development programs while the company works toward sustainable profitability.
Clinical Pipeline ProgressProgression into Stage 2 provides stronger clinical validation for MGC026 than early dose escalation alone. Observed anti-tumor activity and the absence of reported interstitial lung disease or ocular toxicity could improve the asset’s partnering and commercial potential.
Bears Say
Persistent Cash BurnHeavy negative operating and free cash flow shows that the business is still consuming substantial cash to fund operations and development. Continued burn can increase dependence on collaborations or financing and may constrain investment choices before profitability is reached.
Unprofitable OperationsThe company has improved its loss profile but remains below operating breakeven, leaving earnings dependent on further cost control, revenue growth, or successful development outcomes. Persistent negative margins weaken internal funding capacity and make results vulnerable to program or revenue volatility.
External Funding DependenceReliance on external funding is a structural vulnerability for a clinical-stage company whose revenue can depend on partner payments, milestones, royalties, or future commercialization. This may create financing pressure and limit strategic flexibility if development spending remains high.
MacroGenics News
MGNX FAQ
What was MacroGenics’s price range in the past 12 months?
MacroGenics lowest stock price was $1.29 and its highest was $5.08 in the past 12 months.
What is MacroGenics’s market cap?
MacroGenics’s market cap is $228.68M.
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is Nov 04, 2026 which is in 13 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on Aug 13, 2026. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of -$0.078 by $0.388.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -0.32.
How many shares outstanding does MacroGenics have?
MacroGenics has 63,700,188 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of $0.31 in its last earnings report, beating expectations of -$0.078. Following the earnings report the stock price went up 3.431%.
Which hedge fund is a major shareholder of MacroGenics?
Currently, no hedge funds are holding shares in MGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MacroGenics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (73.27% Upside)
$7.00 (73.27% Upside)
Blogger Sentiment
Neutral
MGNX Sentiment 75%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 36.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
104.09%
12-Months-Change
Fundamentals
Return on Equity
-31.27%
Trailing 12-Months
Asset Growth
40.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MacroGenics
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
MGNX Stock 12 Month Forecast
Average Price Target
$7.00
▲(73.27% Upside)
Technical Analysis
Ownership Overview
2.61% Insiders
12.13% Mutual Funds
3.02% Other Institutional Investors
71.93% Public Companies and
Individual Investors